Editas Medicine Higher After Favorable Patent Ruling

Editas Medicine Inc EDIT shares are trading higher by $2.00 (9 percent) at $26.30 in Thursday's session.

The issue is following through on its $5.44 gain from Wednesday's session. That rally was instigated by an announcement confirming a US Patent And Trademark Office decision favorable to Broad Institute in CRISPR Interference.

After a flat open, Editas declined to $23.50 before embarking on its move higher. So far, the ensuing rally has taken the issue to $26.47 and isn't far off that level. That marks the highest level for the issue since it peaked on July 29 at $27.57.